Last updated: August 17, 2026

Examiner: ROBINSON, MIKHAIL O'DONNEL

Tech Center 1600 • Art Units: 1613 1627 1629

This examiner grants 59% of resolved cases

Performance Statistics

58.9%

Allow Rate

-1.1% vs TC avg

160

Total Applications

+41.5%

Interview Lift

1218

Avg Prosecution Days

Based on 124 resolved cases, 2023–2026

5.3%

§101 Eligibility

21.9%

§102 Novelty

40.9%

§103 Obviousness

22.1%

§112 Clarity

App #	Title	Status	Assignee
18570555	E3 Ligase Inhibitors and Methods of Use Thereof	Non-Final OA	The Regents of the University of California
18707062	SELECTION AND TREATMENT OF SUBJECTS HAVING A CIRCULATING MYELOID CELL INFLAMMATORY PHENOTYPE	Non-Final OA	The Board of Trustees of The Leland Stanford Junior University
18787216	INHIBITORS OF MUTANT IDH1 AND IDH2	Non-Final OA	Board of Regents, The University of Texas System
18893545	SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS	Non-Final OA	Bayer Aktiengesellschaft

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.